Suppr超能文献

具有两种不同寡聚结构的人表面活性蛋白A,这两种结构与II型肺泡细胞相互作用的能力不同。

Human surfactant protein A with two distinct oligomeric structures which exhibit different capacities to interact with alveolar type II cells.

作者信息

Hattori A, Kuroki Y, Sohma H, Ogasawara Y, Akino T

机构信息

Department of Biochemistry, Sapporo Medical University School of Medicine, Japan.

出版信息

Biochem J. 1996 Aug 1;317 ( Pt 3)(Pt 3):939-44. doi: 10.1042/bj3170939.

Abstract

The lung lavage fluids from patients with pulmonary alveolar proteinosis have been generally used as a source for human surfactant protein A (SP-A). We have recently found that a multimerized form of SP-A oligomer (alveolar proteinosis protein-I, APP-I) exists besides the normal-sized octadecamer (APP-II) in SP-As isolated from the patients. When analysed by Bio-Gel A15m column chromatography in 5 mM Tris buffer (pH 7.4), the apparent molecular masses of APP-I and APP-II were 1.65 MDa and 0.93 MDa, respectively. Gel-filtration analysis also revealed that APP-II is clearly separated from APP-I in the presence of 2 mM Ca2+ and 150 mM NaCI. We investigated the abilities of both SP-A oligomers to regulate phospholipid secretion and to bind to alveolar type II cells. Although APP-I inhibited lipid secretion, it was clearly a less effective inhibitor than APP-II. IC50 for inhibition of lipid secretion was apparently 0.23 +/- 0.08 microgram/ml (0.14 +/- 0.05 nM) and 0.055 +/- 0.019 microgram/ml (0.059 +/- 0.020 nM) for APP-I and APP-II, respectively. Both proteins bound to monolayers of type II cells in a concentration-dependent manner; however, APP-I clearly had a lower affinity to bind to type II cells. The apparent dissociation contants were, K(d) = 2.31 +/- 0.70 microgram/ml (1.40 +/- 0.43 nM) and 0.89 +/- 0.22 microgram/ml (0.95 +/- 0.24 nM) for APP-I and APP-II, respectively. Excess unlabelled rat SP-A replaced 45% of 125I-APP-I and 77% of 125I-APP-II for type II cell binding. Although 125I-APP-II competed with excess unlabelled APP-I or APP-II, 125I-APP-I failed to compete and instead its binding rather increased in the presence of unlabelled APPs. The biotinylated APP-I bound to APP-I and APP-II coated on to microtitre wells in a concentration-dependent manner, indicating that APP-I interacts with APPs. This study demonstrates that the multimerized form of human SP-A oligomer exhibits the following attributes: (1) the reduced capacity to regulate phospholipid secretion from type II cells, and (2) lower affinity to bind to type II cells, and that the integrity of a flower-bouquet-like octadecameric structure of SP-A oligomer is important for the expression of full activity of this protein, indicating the importance of the oligomeric structure of mammalian lectins with collagenous domains.

摘要

肺泡蛋白沉积症患者的肺灌洗液通常被用作人表面活性蛋白A(SP-A)的来源。我们最近发现,从这些患者分离出的SP-A中,除了正常大小的十八聚体(APP-II)外,还存在一种多聚化形式的SP-A寡聚体(肺泡蛋白沉积症蛋白-I,APP-I)。当在5 mM Tris缓冲液(pH 7.4)中通过Bio-Gel A15m柱色谱分析时,APP-I和APP-II的表观分子量分别为1.65 MDa和0.93 MDa。凝胶过滤分析还表明,在2 mM Ca2+和150 mM NaCl存在下,APP-II与APP-I能清晰分离。我们研究了这两种SP-A寡聚体调节磷脂分泌以及与II型肺泡细胞结合的能力。虽然APP-I抑制脂质分泌,但其抑制效果明显不如APP-II。APP-I和APP-II抑制脂质分泌的IC50分别明显为0.23±0.08微克/毫升(0.14±0.05 nM)和0.055±0.019微克/毫升(0.059±0.020 nM)。两种蛋白都以浓度依赖的方式与II型细胞单层结合;然而,APP-I与II型细胞结合的亲和力明显较低。APP-I和APP-II的表观解离常数分别为K(d)=2.31±0.70微克/毫升(1.40±0.43 nM)和0.89±0.22微克/毫升(0.95±0.24 nM)。过量未标记的大鼠SP-A分别取代了45%的125I-APP-I和77%的125I-APP-II与II型细胞结合。虽然125I-APP-II能与过量未标记的APP-I或APP-II竞争,但125I-APP-I不能竞争,相反,在未标记APP存在时其结合反而增加。生物素化的APP-I以浓度依赖的方式与包被在微量滴定孔上的APP-I和APP-II结合,表明APP-I与APPs相互作用。本研究表明,人SP-A寡聚体的多聚化形式具有以下特性:(1)调节II型细胞磷脂分泌的能力降低,以及(2)与II型细胞结合的亲和力较低,并且SP-A寡聚体的花束状十八聚体结构的完整性对于该蛋白的完全活性表达很重要,这表明具有胶原结构域的哺乳动物凝集素的寡聚体结构很重要。

相似文献

本文引用的文献

2
Pulmonary alveolar proteinosis.肺泡蛋白沉积症
N Engl J Med. 1958 Jun 5;258(23):1123-42. doi: 10.1056/NEJM195806052582301.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验